Escitalopram treatment for depressive disorder following acute coronary syndrome: A 24-week double-blind, placebo-controlled trial

Journal of Clinical Psychiatry

Volumn 76, Issue 1, 2015, Pages 62-68

  Kim, Jae Min ^a,b   Bae, Kyung Yeol ^a,b   Stewart, Robert ^d   Jung, Bo Ok ^a,b   Kang, Hee Ju ^a,b   Kim, Sung Wan ^a,b   Shin, Il Seon ^a   Hong, Young Joon ^a   Kim, Ju Han ^a,c   Shin, Hee Young ^a   Kang, Gaeun ^a,c   Ahn, Youngkeun ^a   Kim, Jong Keun ^a   Jeong, Myung Ho ^a,b   Yoon, Jin Sang ^a,b  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Chonnam National University Hospital   (South Korea)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; PLACEBO; CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; ANGINA PECTORIS; ANTIDEPRESSANT ACTIVITY; ARTICLE; BECK DEPRESSION INVENTORY; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CARDIOVASCULAR FUNCTION; CEREBROVASCULAR ACCIDENT; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DSM-IV; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EVIDENCE BASED PRACTICE; FATIGUE; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HEART INFARCTION; HUMAN; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; PROGNOSIS; SEXUAL DYSFUNCTION; SKIN TINGLING; SOCIAL AND OCCUPATIONAL FUNCTIONING ASSESSMENT SCALE; SWELLING; XEROSTOMIA; AGED; COMPLICATION; DEPRESSIVE DISORDER; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; CITALOPRAM; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84925367782     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.14m09281     Document Type: Article

References (27)

1. Prince M, Patel V, Saxena S, et al. No health without mental health. Lancet. 2007;370(9590):859-877.
2. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry. 2003;54(3):227-240.
3. van Melle JP, de Jonge P, Spijkerman TA, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med. 2004;66(6):814-822.
4. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA. 1998;279(4):287-291.
5. Strik JJ, Honig A, Lousberg R, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med. 2000;62(6):783-789.
6. Glassman AH, O'Connor CM, Califf RM, et al Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):701-709.
7. Honig A, Kuyper AM, Schene AH, et al; MIND-IT investigators. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med. 2007;69(7):606-613.
8. Lespérance F, Frasure-Smith N, Koszycki D, et al CREATE Investigators. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007;297(4):367-379.
9. Hansen BH, Hanash JA, Rasmussen A, et al. Effects of escitalopram in prevention of depression in patients with acute coronary syndrome (DECARD). J Psychosom Res. 2012;72(1):11-16.
10. Kim JM, Bae KY, Kang HJ, et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investig. 2014;11(1):89-94.
11. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561-571.
12. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57.
13. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
14. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389.
15. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised ed. Rockville, MD: National Institute of Mental Health; 1976.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington, DC: American Psychiatric Press Inc; c1994.
17. Epping-Jordan J, Ustun TB. The WHODAS II: leveling the playing field for all disorders. WHO Mental Health Bull. 2000;6:5-6.
18. Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. Am J Cardiol. 1967;20(4):457-464.
19. Kim JM, Kim SW, Stewart R, et al. Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study. Hum Psychopharmacol. 2011;26(1):41-50.
20. Bush DE, Ziegelstein RC, Tayback M, et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol. 2001;88(4):337-341.
21. Rallidis LS, Varounis C, Sourides V, et al. Mild depression versus C-reactive protein as a predictor of cardiovascular death: a three year follow-up of patients with stable coronary artery disease. Curr Med Res Opin. 2011;27(7):1407-1413.
22. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47-53.
23. Stewart JA, Deliyannides DA, Hellerstein DJ, et al. Can people with nonsevere major depression benefit from antidepressant medication? J Clin Psychiatry. 2012;73(4):518-525.
24. Parashar S, Rumsfeld JS, Spertus JA, et al. Time course of depression and outcome of myocardial infarction. Arch Intern Med. 2006;166(18):2035-2043.
25. Cho MJ, Kim JK, Jeon HJ, et al. Lifetime and 12-month prevalence of DSM-IV psychiatric disorders among Korean adults. J Nerv Ment Dis. 2007;195(3):203-210.
26. Yoon J-S. Measuring ethnic differences in response to psychotropic drugs. In: Hindmarch I, Stonier PD, eds. Human Psychopharmacology: Measures and Methods, vol 5. Chichester, UK: John Wiley & Sons Ltd; 1995;3:31-51.
27. Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346 (jan29 3):f288.